Stryker Stock Falls on Q1 Profit and Revenue Miss

TrustFinance Global Insights

Thg 04 30, 2026

2 min read

Stryker Stock Falls on Q1 Profit and Revenue Miss

Stryker's First-Quarter Financials

Medical device maker Stryker reported first-quarter revenue of $6.02 billion and adjusted earnings per share of $2.60. These figures fell short of Wall Street estimates, which stood at $6.35 billion in revenue and $2.98 in earnings per share.

Despite the quarterly miss, the company reaffirmed its full-year adjusted profit outlook, maintaining a range of $14.90 to $15.10 per share.

Operational Headwinds and Segment Performance

The company attributed the weaker results to softer demand for implants and devices used in complex spinal and orthopedic surgeries. Operational disruptions from a recent cyberattack also presented challenges during the quarter.

Sales in Stryker’s largest segment, Medical Surgery and Neurotechnology, missed analyst estimates. However, the Orthopedics segment outperformed, posting sales of $2.81 billion against expectations of $2.51 billion.

Impact on the Market

Following the release of the earnings report, shares of Stryker fell 1.8% in after-hours trading. The market reaction indicates investor concern over the muted demand for certain medical devices and its impact on the company's growth trajectory.

Outlook and Summary

While Stryker's Q1 performance was below expectations, its stable full-year forecast suggests confidence in future performance. Investors will be closely watching for a recovery in device demand and the company's market share competition with rivals like Zimmer Biomet and Johnson & Johnson.